Jnana Therapeutics
BOSTON, MA · Founded 2016 · CIK 0001879148 · Biotech · Acquired
Chemoproteomics platform for small molecule drug discovery
jnanatx.com →- Grants
- —
- No SBIR or STTR on record
- Sector median: 1
- Raised
- $110M
- 2 Form D · Nov 2022
- 47 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 24
- 2 granted · 22 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓202120222023
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $50,000,000 | |
| Private capital raised | Form D · SEC | $59,999,998 |
Form D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1731 | Design Therapeutics, Inc. | — | $171M |
| 1732 | Halia Therapeutics, Inc. | — | $27M |
| 1733 | Iterum Therapeutics plc | — | $127M |
| 1734 | Jnana Therapeutics | — | $110M |
| 1735 | STRYKAGEN CORPORATION | — | — |
| 1736 | MB RESEARCH LABORATORIES, INC. | — | — |
| 1737 | EpimedX, LLC | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Joel BarrishExecutive Officer
- Caroline BeerExecutive Officer
- Brian CaliDirector
- Annie ChenDirector
- Matthew HammondDirector
- Kevin KinsellaDirector
- Joanne KotzDirector · Executive Officer
- Terrance McGuireDirector
- Donald NicholsonDirector
- Douglas PaganExecutive Officer
- Ronald Renaud, Jr.Director
- Carlo RizzutoDirector
- Stuart SchreiberDirector
- George VratsanosExecutive Officer
Patents
- Treating Pku With Spiro-substituted And Other Piperidine Inhibitors Of SLC6A19 Functionapplication
- Small Molecule Inhibitors Of Mammalian SLC6A19 Functiongranted
- Dosing Regimen For Treating Pku With A Piperidine Inhibitor Of SLC6A19 Functionapplication
- Small Molecule Inhibitors Of Mammalian SLC6A19 Functionapplication
- Small Molecule Inhibitors Of Mammalian SLC6A19 Functionapplication
- Small Molecule Inhibitors Of Mammalian SLC6A19 Functionapplication
- Small Molecule Inhibitors Of Mammalian SLC6A19 Functiongranted
- Small Molecule Inhibitors Of Mammalian SLC6A19 Functionapplication
- Treating Chronic Kidney Disease With A Combination Of A SLC6A19 Inhibitor And A GLP-1 Agonistapplication
- Treating Chronic Kidney Disease With A Combination Of SLC6A19 And SGLT2 Inhibitorsapplication
- Bicyclic Heteroaryl-containing Piperidine Inhibitors Of SLC6A19 Functionapplication
- Crystalline Forms Of A Piperidine Inhibitor Of SLC6A19 Functionapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.